N/A N=93 Macrolane Retrospective Study
Women Who Have Had Breast Enhancement With Macrolane VRF
Primary: Number of Adverse Events — 46 number of AE
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 (Macrolane VR30) in Buttocks Reshaping and contouringCellulite (Macrolane VR30) in Buttocks Reshaping and Contouring
Cellulite of the Buttocks
Primary: Number of Patients With Aesthetic Improvement of the Buttocks Using Investigator GAIS — 7 Participants
N/A N=24 Macrolane for Enhancement of the Shape and Fullness of the Female Breast
Breast Enhancement
Primary: Number of Breasts With Successful Placement of the Implant Posterior to the Mammary Gland at 6 Weeks After Treatment — 48 Breasts
Phase 2 N=42 Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
DCIS
Primary: Number of Participants With a Change in Ki-67 Level — 15; 5; 3 Participants — p=0.004
N/A N=51 Psychosocial Outcomes in Online Cancer Support Groups
Breast Cancer
Primary: Scores on the Personal Resource Questionnaire 85. — 50.22; 53.44 Scores on a scale — p=.315
N/A N=9 Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma
HIV
Primary: Peak Plasma Concentration of Etravirine in Plasma — 497.6 ng/ml
N/A N=271 Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer
Breast Neoplasms · Early Detection of Cancer
Primary: Percentage of Women Who Completed a Breast MRI and Mammogram — 8.9; 22.0; 17.8 percentage of participants — p=0.019
N/A N=6 A 7-year Follow up of All Subjects Incuded in Protocol 31GB0106
Breast Augmentation
Primary: To Evaluate if the Subject Has Macrolane Deposits in the Breast Seven Years Post Treatment, Using a Comprehensive MRI Investigation — 4 participants with remaining product
N/A N=6,013 Evaluation of Human Papilloma Virus (HPV) Self-testing to Increase Screening Uptake
Cervical Intraepithelial Neoplasia
Primary: Screening Uptake — 2519; 0; 2618; 599 participants
Phase 3 N=131 Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction
Breast Cancer · Pain, Postoperative · BRCA1 Mutation
Primary: Change From Baseline in Average Pain Scores Using a Numeric Pain Intensity Scale — 2; 3 score on a scale — p=0.43
N/A N=155 Increasing African Immigrant Women's Participation in Breast Cancer Screening
Breast Cancer
Primary: Mammogram Intention — 1.90 score on a scale
Phase 2 N=24 Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer
Breast Cancer
Primary: Estimate Efficacy of Capecitabine 7/7 in Combination With Lapatinib in Patients With HER2 Overexpressed/Amplified, Trastuzumab-refractory, Metastatic Breast Cancer as…
N/A N=290 To Study Polycystic Ovary Syndrome in Taiwanese Women
Polycystic Ovary Syndrome · Metabolic Syndrome · Cardiovascular Disease
Primary: Total Testosterone — 1.5; 2.9 nmol/L — p=<0.05
Phase 3 N=1,831 A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause
Hot Flashes
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 391; 415; 389; 106 participants
Phase 3 N=107 A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery
Intraoperative Ureter Visualization · Abdominolpelvic Surgery
Primary: Investigator Conspicuity Score Difference in Ureter Between WL and NIR-F at 30 Minutes [Adult (Normal/Mild): WL/NIR-F] — 2.7; 4.3 score on a scale — p=<0.001